Salubris(SZ:002294) Hua Yuan Zheng Quan·2025-04-20 06:16Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is experiencing sustained high growth in its Aliskiren ester product line, and an innovative pipeline is about to form [5] - The company reported a revenue of 4.012 billion yuan for 2024, representing a year-on-year growth of 19.22%, and a net profit attributable to shareholders of 602 million yuan, up 3.71% year-on-year [6] - The company is increasing its R&D investment, which accounted for 25.35% of revenue in 2024, amounting to 1.017 billion yuan [6] Financial Summary - Revenue projections for the company are as follows: 3.365 billion yuan in 2023, 4.012 billion yuan in 2024, 4.505 billion yuan in 2025E, 5.436 billion yuan in 2026E, and 6.278 billion yuan in 2027E [5][7] - The projected net profit for 2025 is 661 million yuan, with a year-on-year growth rate of 9.88% [5] - The company’s earnings per share (EPS) are expected to be 0.59 yuan in 2025, with a projected price-to-earnings (P/E) ratio of 60.80 [5][7] - The company’s total assets are projected to reach 10.998 billion yuan in 2025, with total liabilities of 1.980 billion yuan [7]